|
 |
 |
 |
 |
 |
 |
 |
 |
|
BotDB holds extensive information on a total of
90
structures. Protein structures are listed with their PDB ID, description, and other color-coded features including: |
|
| PDB ID | Description | Image | Other features |
| 1E1H | light chain in product bound state |
|
J P Pf D bXm Pm |
| 1XTF | light chain of E224Q Y366F mutant |
|
J P Pf D bXm Pm |
| 1XTG | light chain of E224Q Y366F mutant complexed with SNAP 25 ('polymer 1: light chain with E224Q, Y366F mutations' 'polymer 2: n2 domain of SNAP-25') |
|
J P Pf D bXm Pm |
| 2G7K | light chain bound to small molecule inhibitors |
|
J P Pf D bXm Pm |
| 2G7N | light chain bound to small molecule inhibitors |
|
J P Pf D bXm Pm |
| 2G7P | light chain of R362A/Y365F mutant |
|
J P Pf D bXm Pm |
| 2G7Q | light chain of R362A/Y365F mutant complexed with small molecule inhibitor ArgHX |
|
J P Pf D bXm Pm |
| 2ILP | light chain inhibited by 4-chlorocinnamic hydroxamate |
|
J P Pf D bXm Pm |
| 2IMA | light chain inhibited by 2,4-dichlorocinnamic hydroxamate |
|
J P Pf D bXm Pm Inh |
| 2IMB | light chain inhibited by L-arginine hydroxamate |
|
J P Pf D bXm Pm Inh |
| 2IMC | light chain, residues 1-424 |
|
J P Pf D bXm Pm Inh |
| 2ISE | light chain WT crystal form A |
|
J P Pf D bXm Pm |
| 2ISG | light chain WT crystal form B |
|
J P Pf D bXm Pm |
| 2ISH | light chain WT crystal form C |
|
J P Pf D bXm Pm |
| 2NYY | holotoxin complexed with monoclonal antibody CR1 |
|
J P Pf D bXm Pm |
| 2NZ9 | holotoxin complexed with monoclonal antibody AR2 |
|
J P Pf D bXm Pm |
| 2VU9 | holotoxin binding domain in complex with GT1B |
|
J P Pf D bXm Pm |
| 2VUA | holotoxin binding domain |
|
J P Pf D bXm Pm |
| 3BOK | light chain apo-enzyme |
|
J P Pf D bXm Pm |
| 3BON | light chain with Zn2+ cofactor bound |
|
J P Pf D bXm Pm |
| 3BOO | light chain with N-Ac-CRATKML inhibitory peptide bound |
|
J P Pf D bXm Pm Inh |
| 3BTA | holotoxin |
|
J P Pf D bXm Pm |
| 3BWI | light chain with an acetate ion bound at the active site |
|
J P Pf D bXm Pm |
| 3C88 | light chain with inhibitory peptide RRGC |
|
J P Pf D bXm Pm Inh |
| 3C89 | light chain with inhibitory peptide RRGM |
|
J P Pf D bXm Pm Inh |
| 3C8A | light chain with inhibitory peptide RRGL |
|
J P Pf D bXm Pm Inh |
| 3C8B | light chain with inhibitory peptide RRGI |
|
J P Pf D bXm Pm Inh |
| 3DDA | light chain with a SNAP-25 peptide |
|
J P Pf D bXm Pm |
| 3DDB | light chain with a substrate analog peptide |
|
J P Pf D bXm Pm |
| 3DS9 | a potent peptidomimetic inhibitor of holotoxin |
|
J P Pf D bXm Pm |
| 3DSE | a potent peptidomimetic inhibitor of holotoxin |
|
J P Pf D bXm Pm |
Botulinum Neurotoxin Serotype B (BoNT/B)
| PDB ID | Description | Image | Other features |
| 1EPW | holotoxin |
|
J P Pf D bXm Pm |
| 1F31 | holotoxin complexed with a trisaccharide(sialyllactose) |
|
J P Pf D bXm Pm |
| 1F82 | light chain (chain A) |
|
J P Pf D bXm Pm |
| 1G9A | holotoxin complexed with inhibitor bis(5-amidino-benzimidazolyl) methane (expt:3) |
|
J P Pf D bXm Pm Inh |
| 1G9B | holotoxin complexed with inhibitor bis(5-amidino-benzimidazolyl) methane (BABIM) (expt:1) |
|
J P Pf D bXm Pm Inh |
| 1G9C | holotoxin complexed with inhibitor bis(5-amidino-benzimidazolyl) methane (BABIM) (expt:4) |
|
J P Pf D bXm Pm Inh |
| 1G9D | holotoxin complexed with inhibitor bis(5-amidino-benzimidazolyl) methane (BABIM) (expt:2) |
|
J P Pf D bXm Pm Inh |
| 1I1E | holotoxin complexed with doxorubicin |
|
J P Pf D bXm Pm |
| 1S0B | holotoxin at pH 4.0 |
|
J P Pf D bXm Pm |
| 1S0C | holotoxin at pH 5.0 |
|
J P Pf D bXm Pm |
| 1S0D | holotoxin at pH 5.5 |
|
J P Pf D bXm Pm |
| 1S0E | holotoxin at pH 6.0 |
|
J P Pf D bXm Pm |
| 1S0F | holotoxin at pH 7.0 |
|
J P Pf D bXm Pm |
| 1S0G | Zinc depleted apoform |
|
J P Pf D bXm Pm |
| 1Z0H | recombinant C-fragment |
|
J P Pf D bXm Pm |
| 2ETF | light chain (chains A,B) |
|
J P Pf D R |
| 2NM1 | holotoxin in complex with its protein receptor |
|
J P Pf D bXm Pm |
| 2NP0 | holotoxin complexed with synaptotagamin-II ectodomain |
|
J P Pf D bXm Pm |
Botulinum Neurotoxin Serotype C (BoNT/C)
| PDB ID | Description | Image | Other features |
| 2QN0 | light chain protease |
|
J P Pf D bXm Pm |
Botulinum Neurotoxin Serotype D (BoNT/D)
| PDB ID | Description | Image | Other features |
| 2FPQ | light chain |
|
J P Pf D bXm Pm |
Botulinum Neurotoxin Serotype E (BoNT/E)
| PDB ID | Description | Image | Other features |
| 1T3A | light chain |
|
J P Pf D bXm Pm |
| 1T3C | light chain of E212Q mutant |
|
J P Pf D bXm Pm |
| 1ZKW | light chain of R347A mutant |
|
J P Pf D bXm Pm |
| 1ZKX | light chain of E158A/T159A/n 160A triple mutant |
|
J P Pf D bXm Pm |
| 1ZL5 | light chain of E335Q mutant |
|
J P Pf D bXm Pm |
| 1ZL6 | light chain of Y350A mutant |
|
J P Pf D bXm Pm |
| 1ZN3 | light chain of E335A mutant |
|
J P Pf D bXm Pm |
| 3D3X | light chain in complex with SNAP-25 substrate peptide |
|
J P Pf D bXm Pm |
Botulinum Neurotoxin Serotype F (BoNT/F)
| PDB ID | Description | Image | Other features |
| 2A8A | light chain at a resolution of 2.0A |
|
J P Pf D bXm Pm |
| 2A97 | light chain at a resolution of 1.8A |
|
J P Pf D bXm Pm |
Botulinum Neurotoxin Serotype G (BoNT/G)
| PDB ID | Description | Image | Other features |
| 1ZB7 | light chain |
|
J P Pf D bXm Pm |
Non-experimental Structure of Botulinum Neurotoxin Serotype A (BoNT/A)
| PDB ID | Description | Image | Other features |
| 1UEE | substrate-bound botox light chain |
|
J P Pf D R |
BoNT Substrates
| PDB ID | Description | Image | Other features |
| 1EZ3 | neuronal T-SNARE syntaxin 1a |
|
J P Pf D R Pm |
| 1HVV | self-association of the H3 region of syntaxin 1a: implications for SNARE complex assembly |
|
J P Pf D R Pm |
| 1JTH | a complex between the N-terminal region of SNAP25 and the SNARE region of syntaxin 1a |
|
J P Pf D R Pm |
| 1KIL | VAMP-2-syntaxin 1a-SNAP25-complex (SNARE complex) |
|
J P Pf D R Pm |
| 1N7S | truncated neuronal SNARE complex |
|
J P Pf D R Pm |
| 1SFC | synaptobrevin2-syntaxin1a-SNAP25b (neuronal synaptic fusion complex) |
|
J P Pf D R Pm |
| 1URQ | VAMP-2-syntaxin 1a-SNAP25 (neuronal Q-SNARES) in complex with R-SNARE motif of tomosyn |
|
J P Pf D R Pm |
Hemagglutinin
| PDB ID | Description | Image | Other features |
| 1QXM | hemagglutinin component (HA1) from type C |
|
J P Pf D bXm Pm |
| 1YBI | HA33A from type A |
|
J P Pf D bXm Pm |
| 2E4M | hemagglutinin subcomponent complex (HA-33/HA-17) from type D strain 4947 |
|
J P Pf D bXm Pm |
| 2EHI | HA1 subcomponent of botulinum type C progenitor toxin complexed with N-acetylneuramic acid |
|
J P Pf D bXm Pm |
| 2EHM | HA1 subcomponent of botulinum type C progenitor toxin complexed with N-acetylgalactosamine |
|
J P Pf D bXm Pm |
| 2EHN | HA1 subcomponent of botulinum type C progenitor toxin complexed with galactose |
|
J P Pf D bXm Pm |
| 2ZS6 | HA3 subcomponent of botulinum type C progenitor toxin |
|
J P Pf D bXm Pm |
Tetanus Neurotoxin (TeNT)
| PDB ID | Description | Image | Other features |
| 1A8D | C fragment at a resolution of 1.57A |
|
J P Pf D R |
| 1AF9 | C fragment at a resolution of 2.7A |
|
J P Pf D bXm Pm |
| 1D0H | C fragment complexed with N-acetyl-galactosamine |
|
J P Pf D bXm Pm |
| 1DFQ | C fragment complexed with sialic acid |
|
J P Pf D bXm Pm |
| 1DIW | C fragment complexed with galactose |
|
J P Pf D bXm Pm |
| 1DLL | C fragment complexed with lactose |
|
J P Pf D bXm Pm |
| 1FV2 | C fragment complexed with its ganglioside receptor GT1B analogue ('polymer 1: c-terminal domain of heavy chain' 'polymer 2: sugar(GLC-GAL-NGA-GAL-NAN-SLB-NAN)') |
|
J P Pf D bXm Pm |
| 1FV3 | C fragment complexed with its ganglioside receptor GT1B analogue ('polymer 1: c-terminal domain of heavy chain' 'polymer 2: sugar(GLC-GAL-NGA-GAL-NAN-SLB-NAN)' 'polymer 3: sugar(7-mer)') |
|
J P Pf D bXm Pm |
| 1YVG | light chain |
|
J P Pf D bXm Pm |
| 1YXW | C fragment complexed with tri-peptide |
|
J P Pf D bXm Pm |
| 1YYN | C fragment complexed with disialyllactose |
|
J P Pf D bXm Pm |
| 1Z7H | light chain of I361V mutant |
|
J P Pf D bXm Pm |
Antibody
| PDB ID | Description | Image | Other features |
| 1AQK | human Fab with high affinity for tetanus toxoid |
|
J P Pf D bXm Pm |
Last updated on May 13 2009
| Sponsored by U. S. Army Medical Research Institute of Infectious Diseases (USAMRIID) in collaboration with the National Cancer Institute (NCI) and Advanced Biomedical Computing Center (ABCC).Support for this project was provided by the Defense Threat Reduction Agency Joint Science and Technology Office-Chemical Biological defense (DTRA JSTO-CBD) project 3.10043_07_RD_B and by the National Cancer Institute, National Institutes of Health, under contract No. HHSN261200800001E. | 
|
|
|